Image

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

Recruiting
40 years and older
All
Phase N/A

Powered by AI

Overview

This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).

Description

The mainly purpose of this study is describe the prevalence of COPD of the subjects with 3 types of CVD who are aged 40 years or older, and also observe the effect of cardiopulmonary co management on the short term prognosis of subjects with CVD and COPD.

This study will enroll approximately 3,000 subjects, with approximately 1,000 subjects in each cohort.

Eligibility

Inclusion Criteria:

  1. Give signed written informed consent to participate.
  2. At least 40 years of age at baseline visit.
  3. Previous or newly diagnosed by at least one of the 3 types of CVD which are,
    • Coronary heart disease ( CHD )
    • Atrial fibrillation (AF )
    • Chronic heart failure ( CHF )
  4. Subjects have no absolute contraindications to spirometry testing.
  5. Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.

Exclusion Criteria:

  1. Significant diseases or conditions, which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
  2. Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
  3. Subjects who are not able to provide written informed consent.
  4. Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.

Study details
    Cardiovascular Diseases

NCT06909773

AstraZeneca

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.